SciELO - Scientific Electronic Library Online

vol.16 issue5Description of the clinical outcomes with an amiodarone modified dose for the conversion of acute atrial fibrillation to sinus rhythmAnomalous origin of the right pulmonary artery from the ascending aorta: Description of a clinical case author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Revista Colombiana de Cardiología

Print version ISSN 0120-5633


RUIZ, Álvaro J. Dyslipidemias and cardiovascular risk: time for a new appoach to lipid disorders?. Rev. Colom. Cardiol. [online]. 2009, vol.16, n.5, pp.214-220. ISSN 0120-5633.

Coronary artery disease is an entity with multiple causes. It is the first cause of mortality in the world, and for the year 2025, will be the first cause of morbidity. Given its multi-causal origin, the approach must also be multiple and all factors should be controlled. Dyslipidemia, one of the main risk factors, has several aspects that need attention and control, although the attention has traditionally been focused on LDL-c, disregarding other lipidic subfractions. Classical lipid studies mainly those with statins, have directed their attention to LDL-c, and there are studies in which there is a LDL-c reduction without little or no change in HDL-C. Even though events and mortality risks decrease, significant residual risks can be appreciated. A study with fibrates had the opposite results, showing significant increase in HDL-c without any change in LDL-c, and an interesting decrease in risk but also with a similar risk to that found in previous studies with statins was observed. Studies with multiple interventions that impact all lipidic sub-fractions have shown better significant changes in risk. Addition of niacin extended release to the pool of drugs in combination witn statins, has allowed to achieve a better control of all the lipidic subfractions as well as significant reductions in risk and plaque growth. The effects of the niacin extended release are reduction of LDL-c and triglycerides, increase in HDL-c and also LP(a) reduction, as well as beneficial changes in ApoA and ApoB. Adverse reactions, such as flushing, can be controlled and in many cases avoided, and have shown to be transient and to decrease and even disappear with time.

Keywords : coronary artery disease; dyslipidemia; HDL-c; niacin extended release.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License